Short-term results of renal transplantation have improved considerably in the past 20 yr; however, similar improvements in long-term outcome have not been achieved. The primary cause of late graft loss is chronic rejection that might be treated by gene therapeutic approaches. Ideally, one would like to impair locally the contact between transplant antigen and the host immune system without compromising the generalized immune competence of the recipient. This can be achieved by local expression of the therapeutic protein in the site of interest using gene therapy. Here it is shown that chronic allograft rejection can be prevented effectively by local delivery of recombinant adeno-associated virus (AAV) vectors that encode the CTLA4Ig immunosuppressant protein to the donor kidney in a fully MHC-mismatched rat strain combination. AAV CTLA4Ig prevented progressive proteinuria and protected transplant kidneys from renal structural injury. A population of anergic T cells with regulatory activity, which eventually were responsible for the induction of tolerance, were found in recipient lymph nodes and in the graft as long as 120 d after transplantation. These data indicate that AAV-mediated CTLA4Ig gene transfer to donor graft represents a promising tool to prevent the onset of chronic rejection and circumvent the unwanted systemic adverse effects of the administration of immunomodulatory protein.
I
n the past 20 yr, short-term outcome of clinical transplantation has improved remarkably; however, long-term results have not. Chronic rejection, the major cause of late (Ͼ1 yr) loss of renal allografts, is sustained by both nonimmune events and antigen-specific humoral and cellular responses. Instrumental to the lesions of chronic rejection is T cell activation after alloantigen recognition, which is required for subsequent humoral responses that are a hallmark of chronic rejection.
Optimal T cell activation can be prevented by using CTLA4Ig to block co-stimulatory interactions between the CD28 receptor on T cells and B7 molecules on antigen-presenting cells (1) . While long-term administration of CTLA4Ig is being studied in humans as adjunctive immunosuppressive therapy in renal transplantation, unwanted systemic adverse effects (e.g., susceptibility to infections and malignancy) might be circumvented by gene transfer of CTLA4Ig to the target organ using a vector that would ensure persistent and highly efficient expression of the fusion protein that is confined to the organ level.
We previously showed that gene delivery to the kidney can be achieved by the ex vivo perfusion of the cold-preserved donor graft with a replication-defective adenoviral construct that maintains transgene expression up to 2 wk (2) . Such an approach prevented acute rejection, prolonged graft survival, and yielded temporary unresponsiveness to donor antigens after transplantation of CTLA4Ig-engineered allografts in incompatible rats that were not given additional immunosuppression (3) . The possibility that a similar approach can be applied to chronic rejection has never been addressed. Crucial for long-term immunomodulation via gene therapy is the use of a vector that is able to induce high-level transgene expression when infecting the graft and to drive expression of the therapeutic gene for a prolonged period without exerting any cytotoxic effect or eliciting any inflammatory or immune response. First-generation adenoviral vectors provide unique and effective means of therapeutic gene delivery in several organs, including the kidney, and do not require cell replication for transduction. However, a major disadvantage is that these vectors trigger host immune response and inflammation, which eventually extinguish transgene expression over time (4) . This is why adenovirus cannot be an answer for chronic rejection. Vectors that are based on the nonpathogenic, single-stranded DNA adeno-associated virus (AAV) have the peculiar advantage over adenovirus to transduce efficiently various tissues and to persist for months or years in vivo either after random integration into the host cell genome or in an episomal form (5) . In these vectors, the whole viral genome is deleted, with the exception of two short inverted terminal repeats that are required for packaging, integration, and replication of the viral genome. Moreover, given that no viral proteins are expressed in recombinant AAV, these vectors seem to elicit neither inflammation nor immune response, thus representing, in principle, ideal gene transfer tools to target chronic rejection of transplanted organs.
To verify this possibility, we first examined the potential of recombinant AAV (rAAV) vectors in the transplant setting by evaluating the time course of expression of a reporter transgene after transduction of cold-preserved kidneys followed by their transplantation into a syngeneic animal. We then constructed a rAAV that carried the murine CTLA4Ig cDNA and investigated whether such an alternative way to block the T cell co-stimulatory pathway could effectively modulate chronic allograft rejection in a fully incompatible rat strain transplantation model. , 1996) . Animals had free access to standard rat food and tap water. Kidney transplantation was performed in syngeneic (LW to LW) and in allogeneic combination, as described previously (6) . Ex vivo gene transfer into kidney grafts was performed during cold preservation via injection into the renal artery of 500 l of solution that contained the AAV vectors or saline. Average cold ischemia time was 30 min. Animals that received syngeneic grafts transduced with AAVLacZ were killed at 15, 30, 60, and 90 d for ␤-galactosidase (␤-gal) expression, histology, and assessment of cellular infiltrates.
Materials and Methods

Animals and Operative Procedure
WF to LW renal allograft rats that received cyclosporine (CsA; 5 mg/kg) for 10 d after transplantation to prevent early acute rejection (7) were studied for chronic rejection. Four groups of five rats received a donor kidney that was injected with saline or transduced with AAVLacZ or low-or high-dose AAVCTLA4Ig (2 ϫ 10 11 or 4 ϫ 10 11 viral genome units per animal, respectively). An additional group of syngeneic transplants was used as controls. To rule out that CTLA4Ig that was released by the transduced kidney in the circulation induced systemic immunosuppression, a secondary BN third-party heart graft was performed in LW animals that received a WF kidney that was injected with high-dose AAVCTLA4Ig. After a 10-d course of CsA and 5-d washout, recipient animals received heterotopically the secondary heart graft, the function of which was evaluated daily by palpation. Rejection of allografts was defined as cessation of visible or palpable cardiac contractions.
Production, Purification, and Characterization of rAAV Vectors
The AAV-LacZ and AAV-CTLA4Ig vectors were based on the pTR-UF5 plasmid and on pAAV-MCS backbone (Stratagene, M-Medical, Milan, Italy), respectively. In both constructs, transcription of the inserted gene was under the control of the strong, constitutive cytomegalovirus immediate-early promoter.
Infectious vector stocks were generated by the ICGEB AAV Vector Unit (http://www.icgeb.org/RESEARCH/TS/COREFACILITIES/AVU. htm) in HEK293 cells, cultured in 150-mm-diameter Petri dishes, by co-transfecting each plate with 15 g of each vector plasmid, together with equimolar amounts of the packaging/helper plasmid, pDG (8) , expressing AAV2 and adenovirus helper functions. Viral stocks were obtained by CsCl gradient centrifugation (9) . rAAV titers were determined by measuring the copy number of viral genomes in pooled, dialyzed fractions using real-time PCR and a TaqMan probe (TGG-GAGGTCTATATAAGC).
Morphologic Evaluation
Kidney specimens were fixed overnight in Dubosq-Brazil and dehydrated in alcohol. After paraffin embedding, 3-m sections of the blocks were cut and stained with periodic acid-Schiff reagent. Tubulointerstitial changes were given a score using the Banff method (10) . Glomerulosclerosis was evaluated as percentage of glomeruli that showed sclerotic lesions, considering all glomeruli in each section. For vascular lesions, the number of arteries affected by intimal fibrosis was counted and the data also were expressed as percentage on the total number of arteries in each section. All biopsies were analyzed by the same pathologist, who was unaware of the nature of the experimental groups.
Immunohistology
Mouse mAb were used for the detection of the following antigens: (1) ED1 present in rat monocytes/macrophages (Chemicon, Milan, Italy), (2) CD4 ϩ cell surface glycoprotein (W3/25; Serotec, Oxford, UK), and (3) rat CD8 ϩ cell surface glycoprotein (OX8; Serotec). All antigens were analyzed by indirect immunofluorescence technique. For the detection of intragraft IgG, direct immunofluorescence was performed using a FITC-conjugated goat anti-rat IgG antibody (Jackson Immunoresearch Laboratories, West grove, PA; 30 g/ml). For each marker, the number of cells was counted in at least 10 randomly selected high-power microscope fields (ϫ400) for each animal.
Isolation of Graft-Infiltrating Lymphocytes
Perfused kidneys were minced and incubated with 1 mg/ml type IV collagenase. Supernatant was centrifuged, and leukocytes were separated on density gradient centrifugation using lympholyte-Rat. Phenotype of CD4 ϩ CD25 ϩ cells was assessed by FACS (FACSort; Becton
Dickinson & Co., Mountain View, CA) after labeling with mouse antirat CD25 antibody, OX-39, followed by FITC-conjugated anti-mouse Ig and anti-CD4-PE.
Mixed Lymphocyte Reaction and Co-Culture Studies
Responder LW lymph node cells (1 ϫ 10 6 ) were cultured in triplicate with irradiated (4000 RAD) splenocytes (1 ϫ 10 6 ) from donor WF, third-party BN, or control LW rats, used as stimulators. Mixed lymphocyte reaction (MLR) assays were performed in the absence or presence of 50 IU/ml rIL-2, in complete RPMI for 5 d. For ConA experiments, cells were incubated for 48 h in the presence of 10 g/ml ConA. Cells then were pulsed for 18 h with 1 Ci 3 H-thymidine, and the radioactivity was measured by liquid scintillation counting. The la-beled uptake was expressed as cpm. For co-culture experiments, LW lymph node cells (1 ϫ 10 6 ) were cultured with irradiated splenocytes (1.5 ϫ 10 6 ) from WF, BN, or LW rats in the presence of 0.5 ϫ 10 6 T cells from AAVLacZ and AAVCTLA4Ig treated animals.
Real-Time Reverse Transcription-PCR
Quantitative analysis of TGF-␤, IL-10, IFN-␥, IL-2, and FoxP3 gene expression in graft-infiltrating lymphocytes (GIL) was performed by real-time reverse transcription-PCR based on a TaqMan ABI PRISM 5700 sequence Detection System (PE Applied Biosystems, Monza, Italy) with SYBR Green PCR Master Mix (Applied Biosystems). The amplification profile consisted of 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. Glyceraldehyde phosphate dehydrogenase served as housekeeping gene. ⌬⌬Ct technique to calculate cDNA content in each sample using the cDNA expression in GIL from syngeneic transplanted rats as reference (calibrator) was used.
Analyticals
Proteinuria was determined in 24-h urine samples by modified Coomassie blue G dye-binding assay for proteins with BSA as standard (11) . Creatinine was measured by a Reflotron creatinine test (Roche, Monza, Italy) on whole blood that was collected from the tail vein of anesthetized animals.
Statistical Analyses
Proteinuria and serum creatinine data were log transformed and analyzed by means of repeated measures ANOVA. Multiple comparisons were performed using a Bonferroni correction stating a corresponding P Ͻ 0.005 as statistically significant, to achieve an overall significance level of 0.05. MLR data were compared by means of Mann-Whitney test.
Results
Expression and Localization of the Transgene into the Donor Kidney after AAV Transduction
We first examined the potential for AAV gene transfer in the kidney after intragraft administration of AAVLacZ in kidneys of syngeneic animals killed at various time points from surgery. The grafts were infected during 30 min of cold ischemia. X-gal staining was used to evaluate the time course of expression and localization of ␤-gal. Reporter gene expression in donor kidneys infected with AAVLacZ was readily detectable 15 d after surgery ( Figure 1A 
In Vitro and In Vivo Evaluation of AAVCTLA4Ig Gene Transfer Efficacy
Next, we assessed the ability of AAVCTLA4Ig vector to transduce the human epithelial A549 cell line ( Figure 1B ). CTLA4Ig mRNA expression that was observed in transduced cells was accompanied by the release of the recombinant protein in cell supernatant as measured by ELISA (2.3 and 2.8 ng/ml at days 2 and 4, respectively).
We then tested the AAVCTLA4Ig vector in a fully allogeneic rat renal allograft model, using WF as donor and LW as recipient. Donor kidneys injected with AAVCTLA4Ig were transplanted into recipient rats given a short course (10 d) of lowdose CsA (5 mg/kg per d, intramuscularly) to prevent early acute rejection. Fifteen days after surgery, all animals showed high levels of CTLA4Ig transcript in the kidney specimens ( Figure 1C ).
Long-Term Effect of AAVCTLA4Ig on Renal Function Impairment
The Figure 2 ). AAVCTLA4Ig prevented the development of proteinuria in a dose-dependent manner. The high-dose AAVCTLA4Ig yielded a reduction in urinary protein excretion that averaged 71% compared with untransduced grafts at 120 d (P Ͻ 0.002). Allogeneic untransduced grafts developed mild renal insufficiency by 90 d that progressively worsened at 120 d. Low-dose AAVCTLA4Ig did not protect animals from renal insufficiency, whereas the high dose maintained completely normal renal function comparable to the syngeneic group (P ϭ 0.04 versus the untransduced group; Table 1 ). In DNA samples extracted from kidney specimens obtained at the end of the study period from animals that received the high dose of CTLA4Ig, viral DNA was readily detectable, and its concentration ranged from 1.5 ϫ 10 4 to 4 ϫ 10 4 viral genomes/g cellular DNA, as detected by competitive PCR quantification. CTLA4Ig protein was detected in the serum of animals that received a transplant and were treated with the high dose of AAVCTLA4Ig 15 d after transplantation (2.027 Ϯ 0.6 ng/ml) and became undetectable at day 30. The levels of CTLA4Ig measured in this study were considerably lower than those previously reported either after a peritransplant infusion of CTLA4Ig protein (12) or intragraft gene transfer (12, 13) . Secreted amounts of CTLA4Ig here measured in the circulation were unable to induce systemic immunosuppression. Therefore, third-party secondary heart grafts, performed 15 d after kidney transplantation, were rejected within 13 d in animals that received high-dose AAVCTLA4Ig-transduced kidneys. Furthermore, finding a comparable proliferative response of T cells that were isolated from lymph nodes taken from AAVCTLA4Ig-and AAVLacZ-treated rats to ConA ruled out the possibility that the levels of CTLA4Ig could cause systemic immunosuppression (naïve 32.4 Ϯ 7.1 versus 4680 Ϯ 180 cpm; syngeneic 48.4 Ϯ 4 versus 4435 Ϯ 77 cpm; untransduced allografts 66.8 Ϯ 3 versus 4248 Ϯ 64 cpm; high-dose AAVCTLA4Ig-treated rats 54.8 Ϯ 3 versus 5274 Ϯ 75 cpm; AAVLacZ-treated rats 55.6 Ϯ 3 versus 3780 Ϯ 223 cpm, absence versus presence of ConA, respectively).
Preservation of Renal Morphology in AAVCTLA4Ig-Transduced Grafts
Chronic rejection in the rat is characterized by glomerular basement membrane changes and sclerosis, severe tubular atrophy and interstitial fibrosis, and obliterative intimal fibrosis of arteries. All these changes occurred in our model. At the end of the study period (120 d), both untransduced and AAVLacZtreated allografts showed extensive glomerulosclerosis, characteristic of chronic rejection, which was reduced by 49% by low-dose AAVCTLA4Ig. The high dose completely halted the progression of glomerular lesions to the extent that the percentage of glomerulosclerosis was comparable to that found in syngeneic animals (Table 1 ). Both doses of CTLA4Ig reduced the severity of tubulointerstitial injury equally, whereas the high dose caused the most prominent protective effect on interstitial inflammation and fibrosis. These results show that AAVCTLA4Ig protected transplant kidneys from renal structural injury across this strong responder combination.
Glomerular IgG deposition, an indirect marker of B cell function, increased in allogeneic untransduced animals as compared with syngeneic controls. Whereas low-dose AAVCTLA4Ig partially reduced IgG deposition, the high dose almost normalized it (P ϭ 0.02 versus untransduced allografts; Table 1 ).
Immune Response to Allografts Transduced with AAVCTLA4Ig
Progression of renal disease is associated with infiltration of mononuclear cells, macrophages, and T cells, which participate to parenchyma scarring by synthesizing and secreting fibrogenic cytokines that are responsible for interstitial fibroblast proliferation and matrix accumulation. At the end of the study, chronic rejection of the graft was characterized by interstitial infiltration of ED1 ϩ monocytes/macrophages and CD4 ϩ and showed the presence of 2.3% of CD4 ϩ CD25 ϩ T cells (gated on CD4 ϩ ) in untransduced allografts, which increased to 43% in high-dose AAVCTLA4Ig-treated grafts. Phenotypic analysis of GIL by real-time reverse transcription-PCR showed an increased expression of Th1 and Th2 cytokines (IFN-␥ and IL-10) and the fibrogenic cytokine TGF-␤ in untransduced animals. Conversely, AAVCTLA4Ig at both doses normalized the expression of the analyzed cytokines (P Ͻ 0.005 versus AAVCTLA4Ig at both doses and syngeneic grafts; Figure 4A ). IL-2 also was downregulated by AAVCTLA4Ig. Real-time PCR revealed that FoxP3 expression in GIL from high-dose AAVCTLA4Ig-treated rats was on average 2.5-fold higher than in GIL from untransduced animals (P Ͻ 0.02; Figure 4A , inset).
To address whether high-dose AAVCTLA4Ig gene transfer affected T cell responses in vivo, we evaluated reactivity against donor antigens in a mixed lymphocyte reaction assay in lymph node cells that were isolated at 120 d after transplantation. T cells from animals treated with AAVCTLA4Ig showed hyporesponse to the donor but not to third-party stimulators, which was reversed by the addition of rIL-2 ( Figure 4B and inset) . To evaluate whether hyporesponsive T cells that were generated in vivo after AAVCTLA4Ig gene transfer had regulatory properties, we tested their capacity to affect proliferation of T cells in a naïve MLR (T cells from naïve LW rats in the presence of irradiated splenocytes of WF donor or third-party BN or LW rats). T cells that were isolated from lymph nodes of AAVCTLA4Ig-treated animals significantly (P Ͻ 0.05) inhibited alloreactivity of naïve T lymphocytes to donor WF alloantigens but not to third-party antigen ( Figure 4C ).
Discussion
Crucial for long-term immunomodulation via gene therapy is the use of a vector that is able to induce high-level transgene expression when infecting the graft and to drive expression of the therapeutic gene for a prolonged period. Other attractive features of suitable vectors include their low pathogenicity and the ability to circumvent the host immune response against the viral proteins. rAAV vectors have the peculiar advantage over other gene delivery vehicles to transduce efficiently various tissues and to persist for long periods of time, without exerting any cytotoxic effect or eliciting any inflammatory or immune response.
Intrarenal arterial administration of rAAV that carried green fluorescence protein DNA in the rat resulted in transduction of renal tubular epithelial cells, with the transgene expressed for 6 wk and a relatively modest host immune response (14) . Furthermore, injection of rAAV5 encoding reporter genes into the mouse renal parenchyma yielded transfection of tubular epithelial cells in the vicinity of the injection site as long as 3 mo (15). Here we demonstrate that, in the setting of kidney transplantation, the expression of LacZ after transduction with rAAV2-the most efficient AAV serotype for the transduction of tubular epithelial cells (16)-via renal artery infusion persists in the donor kidney for 90 d, and viral DNA is still detectable at 120 d. The expression of the reporter protein was confined to the tubular epithelial cells, and, most notably, an almost complete absence of inflammatory cell infiltration in the areas of effectively transduced renal tissue was observed. The long-term expression of the transgene can be attributed to both the intrinsic AAV characteristics of stable persistence and to the modest number of immature dendritic cells in the graft that fail to induce a T cell response of sufficient magnitude to eliminate the transduced cells (17) . Once we established the appropriate experimental conditions in a syngeneic setting, we tested the efficacy of AAVCTLA4Ig in a model of chronic rejection of incompatible kidneys. The results obtained show that AAVCTLA4Ig was remarkably effective in preventing progressive proteinuria and protecting transplant kidneys from renal structural injury. So far, no cure exists for chronic allograft dysfunction despite several attempts. The sole possibility is to target nonimmune events, an option that works well in animals (7, 18, 19) but much less so in humans (20) . Previous studies have found that systemic administration of the fusion protein CTLA4Ig or anti-CD28 mAb in addition to low-dose CsA to LW rat that received a Fisher kidney limited chronic rejection and prolonged survival (21) (22) (23) . Inspired by these pivotal observations, we carried out this study using WF (RT1 u ) rats as donors and LW (RT1 l ) rats as recipients, which, being fully mismatched on both MHC class I and II antigens, could be representative of a broader range of clinical settings.
Another interesting finding of this study is the reduction of glomerular IgG deposition, taken as an indirect indicator of B cell function, in AAVCTLA4Ig-transduced animals as compared with uninfected allografts. The beneficial effect of CD28/B7 co-stimulatory blockade was shown previously in lupus-prone mice treated with CTLA4Ig that was administered either as a recombinant protein or by means of an adenoviral vector (24, 25) . Both therapeutic approaches effectively suppressed the production of anti-DNA antibodies, which contributed to decrease nephritis and prolong animal survival.
The effect of CD28-B7 co-stimulatory blockade on alloimmunity can be due to the inhibition of T cells or to the emergence of regulatory T cells (Treg). Here we found the presence of a consistent amount of CD4 ϩ CD25 ϩ T cells among the lymphocytes that infiltrated the graft, which were isolated from AAVCTLA4Ig-treated animals. These cells were in a state of anergy, as shown by reduced expression of both Th1 and Th2 cytokines. Such phenotype was described in previous studies that showed an impaired capacity to produce IL-2 and IL-10 by CD4 ϩ CD25 ϩ Treg. The regulatory nature of these cells also was confirmed by the increased mRNA expression of the transcription factor FoxP3 (26, 27) . The observation that the addition of rIL-2 reversed donor-specific hyporesponsiveness rules out the possibility that CTLA4Ig inhibited T cell responses through the induction of cell deletion. Conversely, our findings indicate that gene therapy with AAVCTLA4Ig allows a population of anergic T cells with regulatory activity to be formed in the graft. Such cells then migrate into secondary lymphoid organs, thereby contributing to maintain donor-specific unresponsiveness as previously reported in other experimental models of tolerance in rodents (28, 29) . In line with this interpretation are data in another model of tolerance that was induced by nondepleting anti-CD4 mAb in sensitizing rats, in which a higher percentage of Treg was found within tolerized heart grafts than in the spleen and draining lymph nodes (30) . By contrast, more recent findings showed the presence of Treg in lymphoid organs of tolerized rat heart recipients as early as 5 d after transplantation but failed to find Treg in the graft (31) . This can be taken to suggest that T cells can be made regulatory elsewhere and track to graft. Therefore, the origin and the trafficking of Treg are dependent on the experimental setting.
That the hyporesponsive state that was induced by CTLA4Ig ) from WF or BN rats in the presence of 0.5 ϫ 10 6 T cells from AAVLacZ-and AAVCTLA4Ig-treated animals. Naïve MLR with 1.5 ϫ 10 6 T cells from naïve animals and 1.5 ϫ 10 6 irradiated splenocytes also was performed as controls. *P Ͻ 0.05 versus LN T cells from AAVLacZtreated animals.
was due in part to indoleamine 2,3-dioxygenase activation in antigen-presenting cells represents an alternative possibility (32) . This is suggested by the observation that, in mice, CTLA4Ig causes the induction of indoleamine 2,3-dioxygenase in splenic dendritic cells that would confer to the latter T cell-regulatory properties (33) . We cannot exclude that CTLA4Ig protects transplanted kidneys from ischemic injury, which in the long term may protect from renal function deterioration (34) .
Conclusion
This study demonstrates that a rAAV vector effectively transduces the graft in syngenic animals and does not induce local host immune response. Long-term and sustained CTLA4Ig gene expression in the graft enables the prevention of renal functional and structural injury associated with chronic rejection in a fully incompatible strain combination. Targeting the CD28/B7 pathway by a gene delivery system that uses vectors with long-lasting expression capacity in the transfected graft is a promising way to inhibit chronic rejection and may have implications for a major unsolved problem in clinical transplantation.
